Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Key Takeaways
- GLP-1 is a hormone your gut releases after meals; GLP-1 RA is the drug class that mimics it
- Incretin is the broader category of meal-triggered gut hormones, which includes both GLP-1 and GIP
- Pure GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, dulaglutide) target one receptor
- Dual agonists (tirzepatide) target two incretin receptors and are technically a separate sub-class
- DPP-4 inhibitors and SGLT2 inhibitors are different drug classes, often confused with GLP-1 medications because they overlap in diabetes treatment
Direct answer
GLP-1 is the hormone, GLP-1 RA is the drug class that mimics the hormone, and incretin mimetic is the broader category that includes GLP-1 RAs plus dual agonists like tirzepatide. The terms overlap but mean different things at different levels of precision. Most clinicians and patients use them interchangeably in casual conversation, which works in context but loses meaning when discussing specific molecules or mechanisms.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The three terms, lined up side by side
- Where the confusion comes from
- The hormone GLP-1, in 90 seconds
- The drug class GLP-1 RA, member by member
- Incretin mimetic as an umbrella term
- What tirzepatide is, technically
- Adjacent classes people confuse with GLP-1
- When the terminology matters and when it doesn't
- How regulatory documents use the terms
- Contrary view: maybe the jargon doesn't matter
- Decision framework
- FAQ
- Sources
The three terms, lined up side by side
Here is the cleanest way to think about it:
| Term | What it refers to | Example |
|---|---|---|
| GLP-1 | The hormone glucagon-like peptide-1, released by your gut after eating | The hormone itself, not a drug |
| GLP-1 RA | Glucagon-like peptide-1 receptor agonist; the drug class that activates the GLP-1 receptor | Semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza) |
| Incretin mimetic | Any drug that mimics an incretin hormone (GLP-1 or GIP) | All GLP-1 RAs plus tirzepatide (dual GLP-1/GIP) |
The relationship is nested. Every GLP-1 RA is an incretin mimetic, but not every incretin mimetic is a GLP-1 RA. The hormone GLP-1 is the natural substance that the GLP-1 RA drugs were designed to imitate.
Where the confusion comes from
People use these terms loosely for three reasons.
The first is that "GLP-1" is shorter than "GLP-1 receptor agonist." When a patient says "I'm on a GLP-1," they almost always mean the drug, not the hormone. The shortened form has won in casual usage. Clinical conversation reflects the shorthand.
The second is that tirzepatide blurred the lines. When Mounjaro arrived in 2022 and Zepbound in 2023, the prescribing experience felt similar to Ozempic and Wegovy: weekly injection, similar side effects, similar weight-loss trajectory. Most clinicians grouped tirzepatide with GLP-1 RAs because the patient experience matched. The technical term "dual incretin agonist" is more precise but less convenient.
The third is that the field is evolving fast. Triple agonists (retatrutide), oral small molecules (orforglipron), and combination products (cagrisema) keep arriving. Older terminology doesn't always fit cleanly. Some sources call the whole space "incretin-based therapies"; others call it "the GLP-1 class." Both are defensible.
The hormone GLP-1, in 90 seconds
Glucagon-like peptide-1 is a 30 or 31 amino acid peptide hormone. It is produced by L-cells in the distal small intestine and colon. The hormone is released into the bloodstream within minutes after eating, particularly in response to carbohydrate and fat reaching the gut.
Its job is to coordinate the body's response to food. It tells the pancreas to release insulin (but only if blood sugar is rising). It tells the pancreas to reduce glucagon secretion. It slows gastric emptying, which keeps you fuller longer. And it acts on appetite centers in the brain to signal satiety.
GLP-1 has a remarkably short biological lifespan. The enzyme DPP-4 breaks it down within about two minutes of release. That is why native GLP-1 cannot be used as a drug. Every GLP-1 medication is a chemically modified version designed to survive DPP-4 and circulate for hours or days.
The drug class GLP-1 RA, member by member
The pure GLP-1 receptor agonists approved by the FDA include these molecules:
- Exenatide (Byetta, Bydureon, Bydureon BCise): The first GLP-1 RA, approved in 2005. Based on exendin-4 from Gila monster venom. Byetta is twice-daily injection; Bydureon is once-weekly.
- Liraglutide (Victoza, Saxenda): Approved 2010 for diabetes, 2014 for chronic weight management at a higher dose. Daily injection. Same molecule as Saxenda but lower dose.
- Lixisenatide (Adlyxin): Approved 2016 for diabetes. Discontinued in the U.S. in 2023 for commercial reasons, not safety.
- Dulaglutide (Trulicity): Approved 2014. Weekly injection. Fusion protein with antibody fragment for long half-life.
- Semaglutide (Ozempic, Wegovy, Rybelsus): Approved 2017 (Ozempic, injectable for diabetes), 2019 (Rybelsus, oral for diabetes), 2021 (Wegovy, injectable for obesity). The most prescribed GLP-1 RA as of 2025.
All five molecules above are pure GLP-1 RAs. They target one receptor: the GLP-1 receptor. They share mechanism, side-effect profile, and contraindications. They differ in half-life, weight-loss magnitude, cardiovascular evidence, and route of administration.
Incretin mimetic as an umbrella term
Incretin refers to gut hormones that stimulate insulin release after eating. There are two known incretin hormones in humans: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide, sometimes called gastric inhibitory peptide). Both are released by intestinal cells in response to food.
An incretin mimetic is any drug that mimics one or both of these hormones at the receptor level. The category includes:
- All GLP-1 receptor agonists (pure GLP-1 mimetics)
- Tirzepatide (dual GLP-1/GIP mimetic)
- Retatrutide (triple agonist: GLP-1, GIP, glucagon; investigational, not FDA-approved)
The term "incretin mimetic" is useful when you want to describe the broader category without specifying which receptors are involved. It is the right term for review articles, regulatory documents, and discussions that span multiple drug classes.
The term "incretin-based therapy" is sometimes used even more broadly to include DPP-4 inhibitors, since they increase your endogenous incretin levels by blocking degradation. That usage is less precise; DPP-4 inhibitors do not mimic incretin action directly.
What tirzepatide is, technically
Tirzepatide is a 39 amino acid peptide that binds both the GLP-1 receptor and the GIP receptor with high affinity. The molecule was engineered to have a longer half-life (about 5 days) than native incretin hormones, allowing weekly subcutaneous dosing.
Approved as Mounjaro (May 2022) for type 2 diabetes and Zepbound (November 2023) for chronic weight management, tirzepatide is the most prescribed dual incretin agonist as of May 2026. Eli Lilly markets both products.
The dual mechanism appears to produce larger weight loss than pure GLP-1 RAs. SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine 2022) reported mean weight loss of about 22.5 percent on tirzepatide 15 mg over 72 weeks. SURMOUNT-5 (head-to-head with semaglutide) confirmed the superiority. Whether this difference is driven by the GIP component, by greater receptor occupancy, or by other factors remains debated.
When someone asks "is tirzepatide a GLP-1," the honest answer is: yes at the level of mechanism (it activates the GLP-1 receptor), but no at the level of pharmacology (it is not exclusively a GLP-1 RA). Most clinicians use the casual yes; most pharmacologists use the careful no.
Adjacent classes people confuse with GLP-1
Several diabetes and weight-loss drugs sit near GLP-1 RAs in clinical practice but belong to different classes.
DPP-4 inhibitors. These oral drugs (sitagliptin/Januvia, saxagliptin/Onglyza, linagliptin/Tradjenta, alogliptin/Nesina) block the enzyme that breaks down your own GLP-1 and GIP. They increase your endogenous incretin levels but do not mimic the hormone. Their effect on glucose is modest, and their effect on weight is roughly neutral. They are not in the same class as GLP-1 RAs.
SGLT2 inhibitors. These oral drugs (empagliflozin/Jardiance, dapagliflozin/Farxiga, canagliflozin/Invokana, ertugliflozin/Steglatro) block glucose reabsorption in the kidney, causing glucose to spill into urine. They produce modest weight loss (about 2 to 3 kg) through caloric loss, not through appetite suppression. They are a completely different class.
Naltrexone-bupropion. Marketed as Contrave for weight management. Combines an opioid receptor antagonist with a dopamine/norepinephrine reuptake inhibitor. Not a GLP-1 medication and not related to incretin biology. Produces about 4 to 5 percent weight loss in trials.
Phentermine-topiramate. Marketed as Qsymia. Combines a stimulant appetite suppressant with an anti-seizure medication. Not a GLP-1 medication.
Orlistat. Marketed as Xenical (prescription) and Alli (over-the-counter). Blocks dietary fat absorption in the gut. Not a GLP-1 medication.
These drugs sometimes appear alongside GLP-1 RAs in obesity treatment algorithms, which contributes to confusion. They are not mechanistically related.
When the terminology matters and when it doesn't
For most patients, the casual usage works fine. Saying "I'm on a GLP-1" conveys the relevant information in most contexts. Saying "I'm on a dual GLP-1/GIP receptor agonist" is accurate but cumbersome.
The terminology matters more when:
- Comparing efficacy. "GLP-1 RAs produce 5 to 15 percent weight loss" obscures the gap between exenatide and semaglutide. Naming the specific molecule is more useful.
- Discussing mechanism. Whether GIP activation matters for weight loss is an active research question. Calling tirzepatide a GLP-1 sidesteps the question.
- Reading clinical trials. Trials are conducted on specific molecules. Generalizing from one trial to "the class" can overstate or understate effects.
- Understanding contraindications. The MEN2 thyroid cancer contraindication applies to GLP-1 RAs and tirzepatide based on rodent data. Other incretin drugs may have different profiles as the pipeline expands.
How regulatory documents use the terms
FDA labeling generally uses the most precise term. The Ozempic prescribing information calls semaglutide "a human GLP-1 receptor agonist." The Mounjaro prescribing information calls tirzepatide "a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist."
European Medicines Agency documents use similar language. Clinical practice guidelines from the American Diabetes Association group both pure GLP-1 RAs and tirzepatide under "GLP-1 receptor agonist and dual GIP/GLP-1 receptor agonist" headings, treating them as related but distinct.
Insurance prior-authorization forms vary. Some list "GLP-1 agonist" and include tirzepatide; others maintain separate categories. The inconsistency in payer documents contributes to patient confusion.
Contrary view: maybe the jargon doesn't matter
There is a reasonable argument that this terminological hairsplitting serves no one.
The patient experience on semaglutide and on tirzepatide is broadly similar: weekly injection, gradual dose escalation, gastrointestinal side effects during titration, sustained weight loss. From a behavioral and clinical standpoint, treating these as one category produces useful generalizations.
The contrast with non-incretin obesity drugs (Contrave, Qsymia, orlistat) is more clinically meaningful than the distinction between pure GLP-1 RAs and dual agonists. Calling them all "GLP-1" or "incretin-based" captures what matters: meal-triggered gut hormone mechanism, gastric and CNS effects, predictable weight loss trajectory.
The counterargument is that imprecise language eventually causes harm. When patients assume Ozempic and Mounjaro are equivalent, they may be surprised by different cost, coverage, or efficacy. When clinicians treat "the GLP-1 class" as homogenous, they may misjudge which drug fits a given patient.
The reasonable middle ground: use casual terminology in casual conversation, use precise terminology when precision matters. Most clinical encounters fall in the casual category. Comparisons across drugs, regulatory discussions, and mechanism conversations call for precision.
Decision framework
If you are talking to a friend about your medication:
- "I'm on a GLP-1" is fine, even for tirzepatide.
- The drug name (Ozempic, Mounjaro, Wegovy, Zepbound) is more informative if you're asked.
If you are talking to a clinician:
- Name the drug. Specificity matters for safety and dosing.
- If you don't remember the name, "the weekly injection for weight loss" or "the diabetes shot" usually triggers the right follow-up.
If you are researching the field:
- Use "GLP-1 receptor agonist" for the pure class.
- Use "dual GIP/GLP-1 receptor agonist" or "twincretin" for tirzepatide.
- Use "incretin-based therapy" or "incretin mimetic" for the broader category.
If you are writing about these drugs:
- Define your terms once and use them consistently.
- Distinguish pure GLP-1 RAs from dual agonists explicitly when efficacy comparisons matter.
- Avoid implying that "GLP-1" and "Mounjaro" mean the same thing in every context.
FAQ
Is GLP-1 the same as GLP-1 RA? No. GLP-1 is the hormone; GLP-1 RA is the drug class that mimics it. In casual speech, people use GLP-1 for the medication, but the technical distinction matters in clinical and research contexts.
What is an incretin mimetic? Any drug that mimics an incretin hormone (GLP-1 or GIP). The category includes all GLP-1 RAs plus dual agonists like tirzepatide.
Why do people use different terms for the same medication? Different levels of precision. GLP-1 is the hormone, GLP-1 RA is the drug class, incretin mimetic is the broader category. People shift terms based on context and audience.
Is tirzepatide a GLP-1? Tirzepatide activates the GLP-1 receptor but is not exclusively a GLP-1 drug. It is a dual GLP-1/GIP receptor agonist. Casual yes, technical no.
What does DPP-4 inhibitor have to do with GLP-1? DPP-4 is the enzyme that breaks down GLP-1. DPP-4 inhibitors block the enzyme to increase your endogenous GLP-1 levels. They are a different class than GLP-1 RAs and produce smaller weight-loss effects.
Is exenatide a GLP-1? Yes. Exenatide is a GLP-1 receptor agonist, based on exendin-4 from Gila monster venom. It was the first FDA-approved GLP-1 medication (2005).
Are SGLT2 inhibitors GLP-1 medications? No. SGLT2 inhibitors work in the kidney to excrete glucose in urine. They are a separate class with a different mechanism.
Why does my doctor say GLP-1 when I take Mounjaro? Clinical shorthand. Most providers group tirzepatide with pure GLP-1 RAs because the patient experience overlaps significantly.
What is the most precise term for these medications? Depends on the drug. Use GLP-1 receptor agonist for semaglutide, liraglutide, exenatide, dulaglutide. Use dual GLP-1/GIP receptor agonist for tirzepatide. Use incretin mimetic for the umbrella category.
Are compounded GLP-1 medications still called GLP-1? Yes, compounded semaglutide is still a GLP-1 RA in terms of mechanism, because it contains the same active ingredient as Ozempic and Wegovy. The "compounded" label refers to manufacturing pathway, not pharmacological class. Compounded versions are not FDA-approved.
What about retatrutide and triple agonists? Retatrutide is a triple agonist (GLP-1, GIP, glucagon). It is an incretin mimetic plus a glucagon agonist. It is investigational and not FDA-approved. FormBlends does not sell or supply retatrutide.
Will the terminology change as new drugs arrive? Probably. As triple agonists, oral GLP-1s, and combination drugs (cagrisema) reach approval, the field may move toward broader terms like "nutrient-stimulated hormone-based therapy" to encompass everything. The current terminology is a snapshot of where the field stands as of 2026.
Sources
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
- Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiological Reviews. 2007.
- Nauck MA et al. Incretin Hormones: Their Role in Health and Disease. Diabetes, Obesity and Metabolism. 2018.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- FDA Prescribing Information. Ozempic (semaglutide). Updated 2024.
- FDA Prescribing Information. Mounjaro (tirzepatide). Updated 2024.
- American Diabetes Association. Standards of Medical Care in Diabetes. 2025.
- Coskun T et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus. Molecular Metabolism. 2018.
- Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metabolism. 2016.
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). New England Journal of Medicine. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform that facilitates connections between patients, licensed prescribers, and U.S.-based pharmacies. We do not provide medical advice, manufacture medications, or dispense drugs ourselves. Any clinical recommendations come from your treating provider, not from FormBlends.
Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide are not FDA-approved products. They are prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions and have not undergone the FDA's standard review for safety, purity, or efficacy. Compounded medications are not equivalent to brand-name products.
Results Disclaimer. Outcomes vary by patient. Trial averages reflect controlled conditions and may differ from individual experience. Adherence, diet, activity, and underlying medical conditions all affect results.
Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Byetta and Bydureon are registered trademarks of AstraZeneca. Januvia, Onglyza, Tradjenta, Jardiance, Farxiga, Invokana, Contrave, Qsymia, Xenical, and Alli are registered trademarks of their respective owners. FormBlends is not affiliated with or endorsed by any of these manufacturers.